Meissa Announces Positive Preliminary Clinical Data on Safety and Immunogenicity of Intranasal COVID-19 Vaccine

• Meissa’s intranasal recombinant live attenuated COVID-19 vaccine, MV-014-212, induced a strong nasal IgA antibody response in seropositive and seronegative adults
• Safety data show that MV-014-012 is highly attenuated, with no serious adverse events reported and no infectious vaccine virus detected from any participants to date
• MV-014-212 was built on the company’s AttenuBlock™ platform and is designed to be appropriately attenuated, genetically stable, and optimized to drive robust, broad, and durable immunity

Excerpt from the Press Release:

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today positive preliminary data from the interim analysis of 49 patients in a Phase 1 clinical study of MV-014-212, the company’s intranasal recombinant live attenuated COVID-19 vaccine (ClinicalTrials.gov Identifier: NCT04798001). The data show that a single adjuvant-free dose of MV-014-212 stimulated a strong nasal IgA antibody response in seropositive and seronegative adults. Doses ranged from 10³ to 10⁵ PFU, with the 10⁵ PFU dose inducing nasal IgA antibody levels that resembled natural immunity to SARS-CoV-2. In addition, safety data at all dose levels indicate MV-014-212 is highly attenuated, with no infectious vaccine virus recovered from any participant and no serious adverse events reported to date. This preliminary data will be presented at the World Vaccine & Immunotherapy Congress taking place November 30th to December 2nd. The Phase 1 clinical study is still enrolling participants, and full results are expected to be presented in a scientific forum next year.

“The preliminary clinical data indicate a single, adjuvant-free, needle-free dose of Meissa’s COVID-19 intranasal vaccine can stimulate a nasal IgA antibody response similar to that seen after SARS-CoV-2 infection, with an important difference – safety,” said Robert Walker, M.D., Chief Medical Officer of Meissa Vaccines. “The initial safety data from this trial combined with our preclinical COVID-19 data and clinical data from Meissa’s RSV vaccine candidate, which was also built on the AttenuBlock platform, support continued clinical development of MV-014-212. We will continue to advance Meissa’s COVID-19 intranasal vaccine in this Phase 1 clinical trial in adults, and we plan to evaluate it as a booster to complement injectable vaccines and initiate a Phase 1 pediatric study next year.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release